Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 14/20 | 0.50 |
| ▸ | OGFRL1 | Q5TC84 | 10/20 | 0.50 |
| ▸ | OPRL1 | P41146 | 5/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.39 |
| ▸ | HTR7 | P34969 | 1/20 | 0.39 |
| ▸ | CFTR | P13569 | 1/20 | 0.37 |
| ▸ | CDK8 | P49336 | 1/20 | 0.35 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2977285 | 0.91 | OPRM1 (0.60) | OPRM1OGFRL1OPRL1LMNAKMT2A | |
| Citric Acid SCHEMBL2966341 | 0.90 | OPRM1 (0.44) | OPRM1OGFRL1OPRL1LMNAKMT2A | |
| SCHEMBL4766511 | 0.88 | OPRM1 (0.51) | OPRM1OGFRL1OPRL1LMNAKMT2A | |
| SCHEMBL2966374 | 0.87 | OPRM1 (0.49) | OPRM1OGFRL1OPRL1LMNAKMT2A | |
| SCHEMBL2976864 | 0.84 | OPRM1 (0.52) | OPRM1OGFRL1OPRL1LMNAKMT2A | |
| SCHEMBL2973500 | 0.83 | OPRM1 (0.50) | OPRM1OGFRL1OPRL1LMNAKMT2A | |
| SCHEMBL2976491 | 0.83 | OPRM1 (0.52) | OPRM1OGFRL1OPRL1CHRM4HTR7 | |
| SCHEMBL2976623 | 0.83 | OPRM1 (0.52) | OPRM1OGFRL1OPRL1LMNAKMT2A | |
| SCHEMBL4724252 | 0.82 | OPRM1 (0.50) | OPRM1OGFRL1OPRL1KMT2ACFTR | |
| Citric Acid SCHEMBL2976393 | 0.82 | OPRM1 (0.50) | OPRM1OGFRL1OPRL1LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1778680-B1 | SPIROCYCLIC CYCLOHEXANE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2008-10-08 | — | — | EP | claimed |
| US-7776848-B2 | Spirocyclic cyclohexane compounds | GRUENENTHAL GMBH (DE) | 2010-08-17 | — | — | US | disclosed |
| US-7776848-B2 | Spirocyclic cyclohexane compounds | GRUENENTHAL GMBH (DE) | 2010-08-17 | — | — | US | disclosed |
| US-7776848-B2 | Spirocyclic cyclohexane compounds | GRUENENTHAL GMBH (DE) | 2010-08-17 | — | — | US | disclosed |
| EP-1778680-B1 | SPIROCYCLIC CYCLOHEXANE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2008-10-08 | — | — | EP | disclosed |
| EP-1968587-A1 | SUBSTITUTED IMIDAZOQUINOLINES, IMIDAZONAPHTHYRIDINES, AND IMIDAZOPYRIDINES, COMPOSITIONS, AND METHODS | Coley Pharmaceutical, Inc. (US) | 2008-09-17 | — | — | EP | disclosed |
| US-20070213351-A1 | Spirocyclic cyclohexane compounds | GRUENENTHAL GMBH (DE) | 2007-09-13 | — | — | US | disclosed |
| US-20070213351-A1 | Spirocyclic cyclohexane compounds | GRUENENTHAL GMBH (DE) | 2007-09-13 | — | — | US | disclosed |
| US-20070213351-A1 | Spirocyclic cyclohexane compounds | GRUENENTHAL GMBH (DE) | 2007-09-13 | — | — | US | disclosed |
| WO-2007075468-A1 | SUBSTITUTED IMIDAZOQUINOLINES, IMIDAZONAPHTHYRIDINES, AND IMIDAZOPYRIDINES, COMPOSITIONS, AND METHODS | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2007-07-05 | — | — | WO | disclosed |
| EP-1778680-A2 | SPIROCYCLIC CYCLOHEXANE DERIVATIVES | Grünenthal GmbH (DE) | 2007-05-02 | — | — | EP | disclosed |
| WO-2006018184-A2 | SPIROCYCLIC CYCLOHEXANE DERIVATIVES | Grünenthal GmbH (DE) | 2006-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213351-A1 | Spirocyclic cyclohexane compounds | PKD1, PKD2, NR3C2 | OPRM1 768/4885OGFRL1 1860/4885OPRL1 558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.